• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

    43.58 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7
    Open 43.58
    Bid (Size) 38.00 (100)
    Ask (Size) 69.72 (200)
    Prev. Close 43.58
    Today's Range 43.58 - 43.58
    52wk Range 6.710 - 47.36
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
    Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical... 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
    This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +9.6%
    +9.6%
    1 Month
    +9.6%
    +9.6%
    3 Month
    +31.1%
    +31.1%
    6 Month
    +185.8%
    +185.8%
    1 Year
    +190.5%
    +190.5%

    More News

    Read More
    News headline image
    Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Participate in Four Upcoming Investor Conferences
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
    Via MarketBeat
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    News headline image
    Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    News headline image
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
    Via Investor's Business Daily
    News headline image
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027 ↗
    Via Chartmill
    News headline image
    Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Maze Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
    Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
    The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
    What is the current price of Maze Therapeutics, Inc. - Common Stock?
    The current price of Maze Therapeutics, Inc. - Common Stock is 43.58
    When was Maze Therapeutics, Inc. - Common Stock last traded?
    The last trade of Maze Therapeutics, Inc. - Common Stock was at 01/30/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.